Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
PNS lead and generator, intrathecal pump and catheter. Main billing specialty: pain management.
Medicare fee-for-service peripheral nerve stimulation & intrathecal pumps cases in the 39 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (174 state-years, 2020–2024): read it as a direction with a margin.
Professional codes (what the surgeon bills): CPT 64555, 64590, 62362, 62350.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 353 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 11 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Medtronic | 277 |
| Infusyn Therapeutics | 33 |
| Intera Oncology | 29 |
| Bioness | 3 |
| Bioventus | 3 |
| Boston Scientific | 2 |
| Neuspera Medical | 2 |
| Curonix | 1 |
| Micron Medical | 1 |
| Nalu Medical | 1 |
| Stimwave Technologies Dba Stimq | 1 |
The 10 busiest do 39% of the cases CMS names in Texas; 34 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 5,025 | 365,4360%/yr | 0%/yr | 446,400 in 2030+3.4%/yr |
| Spinal cord & DRG stimulation | 668 | 24,248−3.1%/yr |
Every procedure · Markets by state · Device companies · Compare two states
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 60 | 4,698+15%/yr | +15%/yr | 2.01.8× | 72% | 9,310 in 2030+12%/yr |
| Florida | 65 | 3,941+8.8%/yr | +8.8%/yr | 1.61.4× | 74% | 5,860 in 2030+6.8%/yr |
| California | 35 | 2,932+9.5%/yr | +9.5%/yr | 0.80.7× | 78% | 6,310 in 2030+14%/yr |
| Ohio | 26 | 1,792+4.2%/yr | +4.2%/yr | 1.51.3× | 20% | 2,660 in 2030+6.8%/yr |
| Arizona | 23 | 1,632+19%/yr | +19%/yr | 2.01.8× | 90% | 3,070 in 2030+11%/yr |
| New York | 22 | 1,267+7.6%/yr | +7.6%/yr | 0.60.6× | 39% | 2,170 in 2030+9.4%/yr |
| Pennsylvania | 15 | 1,231+6.1%/yr | +6.1%/yr | 0.80.7× | 44% | 1,540 in 2030+3.8%/yr |
| Georgia | 20 | 1,195+14%/yr | +14%/yr | 1.31.1× | 62% | 2,360 in 2030+12%/yr |
| North Carolina | 21 | 1,154+13%/yr | +13%/yr | 1.10.9× | 42% | 1,560 in 2030+5.2%/yr |
| Indiana | 16 | 1,1110%/yr | 0%/yr | 1.51.3× | 70% | 1,390 in 2030+3.8%/yr |
| Tennessee | 23 | 1,041+6.2%/yr | +6.2%/yr | 1.41.2× | 47% | 2,170 in 2030+13%/yr |
| Oklahoma | 21 | 1,024+2.9%/yr | +2.9%/yr | 2.01.7× | 28% | 1,160 in 2030+2.1%/yr |
| Illinois | 14 | 1,015+11%/yr | +11%/yr | 0.70.6× | 41% | 2,110 in 2030+13%/yr |
| South Carolina | 17 | 936+18%/yr | +18%/yr | 1.31.1× | 42% | 2,480 in 2030+18%/yr |
| Arkansas | 21 | 852+4.7%/yr | +4.7%/yr | 2.11.9× | 57% | 980 in 2030+2.4%/yr |
| Massachusetts | 17 | 831+11%/yr | +11%/yr | 0.80.7× | 6% | 820 in 2030−0.3%/yr |
| Missouri | 16 | 810+4.4%/yr | +4.4%/yr | 1.21.1× | 32% | 1,190 in 2030+6.6%/yr |
| Kentucky | 14 | 792+1.1%/yr | +1.1%/yr | 1.61.4× | 17% | 700 in 2030−2%/yr |
| Wisconsin | 8 | 775+8.3%/yr | +8.3%/yr | 1.31.1× | 50% | 1,500 in 2030+12%/yr |
| New Jersey | 8 | 739+5.9%/yr | +5.9%/yr | 0.70.6× | 58% | 950 in 2030+4.2%/yr |
| Maryland | 12 | 704+23%/yr | +23%/yr | 0.80.7× | 89% | 1,180 in 2030+9%/yr |
| Michigan | 9 | 674−6.2%/yr | −6.2%/yr | 0.70.6× | 49% | 680 in 20300%/yr |
| Kansas | 14 | 652+2.5%/yr | +2.5%/yr | 1.51.4× | 52% | 990 in 2030+7.2%/yr |
| Washington | 8 | 573+7.4%/yr | +7.4%/yr | 0.70.6× | 55% | 1,090 in 2030+11%/yr |
| Virginia | 13 | 571−0.7%/yr | −0.7%/yr | 0.50.5× | 30% | 670 in 2030+2.7%/yr |
| Minnesota | 10 | 570+1.3%/yr | +1.3%/yr | 1.11.0× | 65% | 1,150 in 2030+12%/yr |
| Colorado | 10 | 515+13%/yr | +13%/yr | 1.00.9× | 55% | 1,080 in 2030+13%/yr |
| Mississippi | 13 | 445+2.3%/yr | +2.3%/yr | 1.11.0× | 76% | 590 in 2030+4.7%/yr |
| Louisiana | 4 | 441+6.5%/yr | +6.5%/yr | 1.00.9× | 46% | 410 in 2030−1.4%/yr |
| Nebraska | 7 | 421+7.4%/yr | +7.4%/yr | 1.51.4× | 66% | 620 in 2030+6.8%/yr |
| Idaho | 4 | 403+11%/yr | +11%/yr | 1.81.6× | 20% | 790 in 2030+12%/yr |
| Oregon | 4 | 325+4.4%/yr | +4.4%/yr | 0.70.6× | 91% | 1,740 in 2030+32%/yr |
| Alabama | 6 | 319+4.8%/yr | +4.8%/yr | 0.70.6× | 49% | 670 in 2030+13%/yr |
| Nevada | 2 | 316−0.6%/yr | −0.6%/yr | 1.00.9× | 71% | 550 in 2030+9.6%/yr |
| Utah | 1 | 290+14%/yr | +14%/yr | 1.21.1× | 60% | 570 in 2030+12%/yr |
| Connecticut | 5 | 276+9.9%/yr | +9.9%/yr | 0.80.7× | 30% | 610 in 2030+14%/yr |
| Iowa | 3 | 187+13%/yr | +13%/yr | 0.40.4× | 34% | 470 in 2030+17%/yr |
| South Dakota | 7 | 186+0.7%/yr | +0.7%/yr | 1.41.2× | 0% | 230 in 2030+3.3%/yr |
| West Virginia | 3 | 158+6.2%/yr | +6.2%/yr | 0.70.6× | 27% | 100 in 2030−7%/yr |
Product codes: GZF (stimulator, peripheral nerve, implanted (pain relief)), LKK (pump, infusion, implanted, programmable). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +24 pts since 2019, to 59%.
| 28,100 in 2030+2.5%/yr |
In 2025, 15 companies reported engagement with surgeons in the covered states worth $6.4M in consulting, speaking, meals and travel tied to these products, about $11K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.